ERBB2 and breast carcinoma: In this study, we assessed the expression of CD147, CD146, CD73, and MHC class I across a panel of breast cancer cell lines representing triple-negative (MDA-MB-231, and HCC38), hormone receptor-positive (MCF7), and HER2-positive (MDA-MB-453) subtypes.